Who is sponsoring NCT04974879?

NCT04974879 is sponsored by Qingdao Central Hospital.

What drugs are being tested in NCT04974879?

Interventions in NCT04974879: Osimertinib Oral Tablet.

What condition does NCT04974879 study?

NCT04974879 studies Carcinoma, Non-Small-Cell Lung.

Is NCT04974879 still recruiting?

NCT04974879 is currently status unknown. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT04974879

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Status unknown Phase 2 Last updated 29 March 2023

What this trial tests

Phase 2 trial testing Osimertinib Oral Tablet in Carcinoma, Non-Small-Cell Lung in 20 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
31 July 2024

31 December 2024

Quick facts

Lead sponsor	Qingdao Central Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 July 2021
Primary completion	31 July 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Osimertinib Oral Tablet

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →

Sponsor

Qingdao Central Hospital

Who can join

Adults 18 to 80, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is no muture method to treat EGFR 20 insertion mutation non-small-cell lung cancer (NSCLC). the he purpose of this study is to study osimertinib combined with bevacizumab in the management of it.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives.
Hou J, Li H, Ma S, He Z, et al · · 2022 · cited 44× · PMID 35418149 · DOI 10.1186/s40364-022-00372-6
Advances in the management of non-small-cell lung cancer harbouring <i>EGFR</i> exon 20 insertion mutations.
Low JL, Lim SM, Lee JB, Cho BC, et al · · 2023 · cited 17× · PMID 36756143 · DOI 10.1177/17588359221146131
Optimizing the clinical management of <i>EGFR</i>-mutant advanced non-small cell lung cancer: a literature review.
Passiglia F, Bironzo P, Bertaglia V, Listì A, et al · · 2022 · cited 10× · PMID 35693274 · DOI 10.21037/tlcr-22-1
Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.
Zhou G, Guo L, Xu J, Tang K, et al · · 2024 · cited 7× · PMID 38304850 · DOI 10.1177/17588359241227677
First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H, Zhang X, Liu X, Zhao J, et al · · 2023 · cited 6× · PMID 38206746 · DOI 10.1097/md.0000000000036667
[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC  (2022 Version)].
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee, Anti-cancer Drug Safety Management Committee (ASMC). · · 2022 · cited 6× · PMID 36172727 · DOI 10.3779/j.issn.1009-3419.2022.101.47

Verify or expand the search:

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other Qingdao Central Hospital trials

Trials by the same sponsor.

NCT07090525 — Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions · Phase 2 · recruiting
NCT07090031 — Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer · Phase 2 · active not recruiting
NCT07322783 — Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification · Phase 2 · recruiting
NCT06500234 — Nutrition Impact on Immunotherapy of Cancer · Phase 3 · recruiting
NCT06514118 — Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04974879 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qingdao Central Hospital
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04974879.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing